Yngvar Floisand

 Arog Pharmaceuticals and DAVA Oncology, and researcher at CanCell University of Oslo, Norway

Medical Director at Arog Pharmaceuticals and DAVA Oncology and affiliated as a researcher at CanCell at the University of Oslo. 

Dr Floisand MD PhD, graduated from Heinrich Heine University in Düsseldorf in 1995 and trained Internal Medicine and Hematology in Oslo, Norway.

He was Clinical and Research Lead for AML at Oslo University Hospital from 2012 – 2020 and has special interest in AML and acute graft-versus-host disease after allogeneic stem cell transplantation

He has been PI of numerous clinical trial and a member of several international collaborative groups.

From 2020 – 2022, he was Clinical Research Lead and Ass. Director of Stem Cell Transplantation and Celllular Therapy at Clatterbridge Cancer Centre, Liverpool, UK.

Currently, he is Medical Director at Arog Pharmaceuticals and DAVA Oncology and affiliated as a researcher at CanCell at the University of Oslo.

He is author and co-author of more than 70 publications in peer reviewed journals.